Nautilus Biotechnolgy
NAUT
44 hedge funds and large institutions have $165M invested in Nautilus Biotechnolgy in 2021 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 16 closing their positions.
2% more funds holding
Funds holding: 43 → 44 (+1)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
1% less call options, than puts
Call options by funds: $393K | Put options by funds: $395K
7.88% less ownership
Funds ownership: 85.54% → 77.66% (-7.9%)
25% less capital inflows, than outflows
Capital inflows: $34.2M | Capital outflows: $45.4M
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alpha Wave Global
New York
|
+$8.44M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.8M |
| 3 |
Affinity Asset Advisors
New York
|
+$5.39M |
| 4 |
Pura Vida Investments
New York
|
+$4.1M |
| 5 |
Echo Street Capital Management
New York
|
+$3.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sage Rock Capital Management
New York
|
-$5.81M |
| 2 |
Governors Lane
New York
|
-$5.64M |
| 3 |
Suvretta Capital Management
New York
|
-$3.95M |
| 4 |
Glazer Capital
New York
|
-$3.47M |
| 5 |
HP
Hound Partners
New York
|
-$2.98M |
NAUT Hedge Fund Activity: Q1 2021 in Review
44 of the 5,715 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q1 2021, worth a combined $165M — up 15% from $143M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new NAUT positions and 16 closed out — a net gain of 1 holder — while 5 added to existing stakes and 12 trimmed.
The largest buyer was Alpha Wave Global, opening a new position worth an estimated $8.44M. The largest seller was Sage Rock Capital Management, exiting entirely with an estimated $5.81M sold.
- 44 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q1 2021, up from 43 in Q4 2020.
- Funds reported $165M of Nautilus Biotechnolgy stock for Q1 2021, up 15% quarter-over-quarter.
- 17 funds opened new Nautilus Biotechnolgy positions in Q1 2021 and 16 closed out, a net change of +1 holder.
- The largest Nautilus Biotechnolgy buyer in Q1 2021 was Alpha Wave Global, an estimated $8.44M added.
- The largest Nautilus Biotechnolgy seller in Q1 2021 was Sage Rock Capital Management, an estimated $5.81M sold.
Based on aggregated 13F filings for Q1 2021.